Voices
Hidehito Horinouchi and David Gandara: ASCO Living Guideline Update in Stage IV NSCLC
David Gandara and Hidehito Horinouchi

Hidehito Horinouchi and David Gandara: ASCO Living Guideline Update in Stage IV NSCLC

David Gandara, Co-Director of the Center for Experimental Therapeutics at the UC Davis Comprehensive Cancer Center, shared a post by Hidehito Horinouchi, Assistant Chief of the National Cancer Center Hospital, on X, adding:

”ASCO Living Guideline in NSCLC. Thanks Hidehito Horinouchi for posting. By far the most transparent. Practicing Oncologists need to know what is strongly endorsed, not just a laundry list of every approved regimen. Bravo ASCO.”

Quoting Hidehito Horinouchi’s post:

”ASCO Living Guideline update:

Stage IV NSCLC without driver alterations 2026.3.1
Latest update incorporating new evidence for ICI-based regimens in stage IV NSCLC․”

Title: Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.1

Authors: Lyudmila Bazhenova, Nofisat Ismaila, Greg Durm, Janet Freeman-Daily, Hidehito Horinouchi, Gary R. MacVicar, Deebya Raj Mishra, Bruna Pellini, Erin L. Schenk, Navneet Singh, and Natasha B. Leighl

Read The Full Article in Journal of Clinical Oncology.

Hidehito Horinouchi and David Gandara: ASCO Living Guideline Update in Stage IV NSCLC

Other Articles Featuring David Gandara and Hidehito Horinouchi on OncoDaily.

and Natasha B. Leighl ASCO Authors: Lyudmila Bazhenova Bruna Pellini cancer David Gandara Deebya Raj Mishra Erin L. Schenk Gary R. MacVicar Greg Durm Hidehito Horinouchi Janet Freeman-Daily Lung cancer Lyudmila Bazhenova Navneet Singh Nofisat Ismaila NSCLC Oncology OnoDaily